Aaron Ondrey compensation by year
ROCKET PHARMACEUTICALS Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $362,662 |
| Bonus | $0 |
| Stock awards | $1,249,988 |
| Option awards | $1,249,983 |
| Non-equity incentive | $117,502 |
| Pension and deferred compensation | $0 |
| All other | $9,628 |
| Total | $2,989,763 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 30, 2025, accession 0001140361-25-016656, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-25-016656. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 46,781 | $588,637 | — |
| Option | 69,337 | — | $26.72 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2024 proxy (filed April 30, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-07-03 | Sale | — | 1,477 | $2.88 | 128,173 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ROCKET PHARMACEUTICALS’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $6,841,407 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | $6,696,055 |
| Aaron Ondrey · this page | Chief Financial Officer, Principal Financial Officer | $2,989,763 |
| Jonathan Schwartz | Chief Medical and Gene Therapy Officer | $2,364,309 |
| Martin Wilson | General Counsel and Chief Corporate Officer, Senior VP | $2,113,954 |
| John Militello | Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President | $1,175,588 |
The full ROCKET PHARMACEUTICALS compensation record
free company briefThis page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ROCKET PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.